The American Journal of Managed Care: Ianalumab Shows Disease-Modifying Potential for Early ITP in the Phase 3 VAYHIT2 Trial Ianalumab Shows Disease-Modifying Potential for Early ITP in the Phase 3 VAYHIT2 Trial Immune thrombocytopenic purpura (ITP) is a blood disorder. With this disease, you have a lower amount of platelets than normal in your blood. Platelets are blood cell fragments that help with blood clotting.

Understanding the Context

Having fewer platelets can cause easy bruising, bleeding gums, and internal bleeding. Immune thrombocytopenia (ITP; also called idiopathic thrombocytopenic purpura, immune thrombocytopenic purpura) is an acquired thrombocytopenia caused by autoantibodies against platelet antigens. It is one of the more common causes of thrombocytopenia in otherwise asymptomatic adults. Diagnosis of ITP involves identifying a low platelet count through a complete blood count, a common blood test.

Key Insights

However, since the diagnosis relies on excluding other potential causes of a low platelet count, additional investigations, such as a bone marrow biopsy, may be necessary in certain cases. Immune thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting. People with the disease have too few platelets in the blood. ITP occurs when certain immune system cells produce antibodies against platelets. Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...

Final Thoughts

Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...